



BM1406: Ion Channels and Immune Response toward a global understanding of immune cell physiology and for new therapeutic approaches (IONCHAN-IMMUNRESPON)

> Seventh MEETING 8-9th March 2017 REPORT

University of Dublin DCU



Agenda Management Committee Meeting

COST Action no. BM1406

Action Title: Ion Channels and Immune Response toward a global understanding of immune cell physiology and for new therapeutic approaches (IONCHAN-IMMUNRESPON) Venue Belgrade, Serbia from _8th March_ to _9th March 2018

- 1. Welcome to participants
- 2. Adoption of agenda
- 3. Approval of minutes and matters arising of last meeting
- 4. Update from the Action Chair
 - a. Status of Action, including participating countries
 - b. Action budget status
 - c. STSM status and new applications
- 5. Promotion of gender balance and of Early Stage Researchers (ESR)
- 6. Update from the Grant Holder
- 7. Update from the COST Association
- 8. Follow-up of MoU objectives
 - a. Progress report of working groups
- 9. Scientific planning
 - a. Scientific strategy
 - b. Action Budget Planning
 - c. Long-term planning (including anticipated locations and dates of future activities)
 - d. Dissemination planning (Publications and outreach activities)
- 10. Requests for new members
- 11. Non-COST applications to the Actions
- 12. AOB
- 13. Location and date of next meeting,
- 14. Summary of MC decisions
- --
- --
- 15. Closing

1. Welcome to participants

- a. 2/3 of country representatives
- b. 26 countries in BM1406
- c. 2/3 = 17 countriesd. Today: 19 /26 countries
- e. 23 MC participants (women sex ration 50 %)
- f. 48 participants in Dublin meeting

2. Adoption of agenda

OK

3. Approval of minutes and matters arising of last meeting

No report because the MC has not reached the chorum.

- 4. Update from the Action Chair
 - a. Status of Action, including participating countries

New country The Netherlands. The national representative must be contacted by the Pr. - Mihai Netea (The Netherlands) for their nomination as national representative of the Netherland Decision approved by unanimous vote of participants

- b. Action budget status
- c.

We spent only 41 % of the budget of the GP3. The meeting in Dublin will be around 50,000.00 euros that will raise up the spent budget to #80%.

c. STSM status and new applications

For the GP3 6 missions, both young and senior fellows as well

5. Promotion of gender balance and of Early Stage Researchers (ESR)

- MC committee
 - Gender ratio
 - MC + substitutes = 13 w/ 23
 - Sex ratio = 50 % •
- WG members
 - 27w / 48 (56,25)
- STSM = majority of women 5w /6

This meeting in Dublin

MC members = 27 women / 21 men Scientific program 8 women speakers out of 16 talks

6. Update from the Grant Holder

1. Budget GP3; 130,383,92 euros 41 % expensed without Dublin meeting

New budget 133,833.00 euros for the GP4,

• GP3 amount spent

Actions / BM1406 / Periods / Manage Grant 3

				Expenditure	enditure				
	Grant budget (a)	Actuals (b)	Accruais (c)	Total (d=b+c)	Forecast (0)	Total (f=d+e)	(g=f-a)		
Total Meeting	87 610.00	26 261.01	6 530.00	32 791.01	36 800.00	69 591.01	-18 018.99		
Total Training School	10 400.00	10 400.00	0.00	10 400.00	0.00	10 400.00	0.0		
Total Short Term Scientific Mission (STSM)	22 500.00	6 850.00	3 500.00	10 350.00	10 000.00	20 350.00	-2 150.00		
Total Inclusiveness Target Countries Conference Grant (ITC CG)	7 473.92	0.00	0.00	0.00	7 473.92	7 473.92	0.0		
Total Action Dissemination	2 400.00	0.00	0.00	0.00	0.00	0.00	-2 400.00		
Total Other Expenses Related to Scientific Activities (OERSA)	0.00	0.00	0.00	0.00	0.00	0.00	0.0		
Total Networking expenditure	130 383.92	43 511.01	10 030.00	53 541.01	54 273.92	107 814.93	-22 568.91		
Total Eligible Networking expenditure	130 383.92	43 511.01	10 030.00	53 541.01	54 273.92	107 814.93	-22 568.91		
Total FBAC 15% of Eligible Networking expenditure	19 557.59	6 526.65	1 504.50	8 031.15	8 141.09	16 172.24	-3 385.3		
Total Eligible Costs	149 941.51	50 037 66				123 987.17			

2. STSM status and new applications

Names	Ge	enre laboratory	STSM place Statu	us C	OST Fund	ls duration
Mr Juan José Martínez	м	Pablo Pelegrin, Clinical University Hospital Virgen de la Arrixaca	Friedrich Nolte, Institut für Immunologie, Hamburg (DE),	PhD. Student	2 500 00	2017-05-02 to 2017-07-31 (90 days)
Ms Inês Vieira da Silva	F	Faculty of Farmacy, University of Lisbon, Lisboa (PT),	Pablo Pelegrin, BioMedical Research Institute of Murcia (IMIB-Arrixaca), Murcia (ES),	PhD. Student	2 500 00	2017-09-10 to 2017-12-09 (90 days)
ESTER Katja	F	Ruđer Bošković Institute Zagreb, Croatia	Dr Jost Ludwig, Laboratory of Bioenergetics and Membrane Physiology	ESR		2017-06-19 to 2017-07-09 (21 days)
Anna-Maria Miederer	F		, , , , , , , , , , , , , , , , , , , ,	PhD. Student		2017-06-11to 2017-06-30 (20 days)
Ruth Murrell- Lagnado	F		Dr S. Roger (Tours)- Inserm U1069 Nutrition, Croissance et cancer	PI		2017-06-11to 2017-06-15 (5 days)
Stéphanie Chadet	F	Ruth Murrell L, Univ	Dr S. Roger (Tours)- Inserm U1069 Nutrition, Croissance et Cancer10 Bd Tonnellé, 37032 Tours, France	post doc	680,00	2017-06-05 to 2017-08-2017

No new applications until today.

7. Update from the COST Association

1. Dates

Dates for the GP4 1st May 2018 to 30th March 2019 !!! with some restrictions concerning the expenses during the last month.

2. Evaluation in the 24 month report

item	Evaluation by rapporteur	
I. Review of Progress	The Action is progressing appropriately with achievement of half of the MoU objectives and delivery of half of the MoU deliverables	Good
II. Review of the Networking	The subject of the action and the groups involved suggest that the action might have a great impact "the short- to long-term scientific, technological, and / or socioeconomic changes produced by a COST Action, directly or indirectly, intended or unintended" but more information would be necessary to clearly evaluate this topic.	Very good
III. Review of Impacts	Multiple highly significant impacts are reasonably foreseen for the future OR one highly or moderately significant impact is already observed [Very Good]	Very good
IV. Review of Dissemination and exploitation of Action results	The activities undertaken focusing on dissemination and exploitation were ineffective [Poor]	0
V. Review of Action Success(s)	The ACTION states as a point of success the occurrence of 5 meetings. This is interesting but there is no information on the participation of the members on these meetings, neither the minutes for the meetings. A very important achievement was the publication of a co-edited book "NLR Proteins, Methods in Molecular Biology"	Good/?
VI. Review of the management of the Action budgets	Budget was spent bringing to the meeting invited speakers that represented added valued for the Action. Budget was spent bringing to the meeting invited speakers that represented added valued for the Action	Very good

presentation and analyses of the report. Discussion on what could be done to improve dissemination.

3. New tool from COST office

COST Connect



Discussion about how can we use this tool?

4. Presentation of the final report

Requested one month after the end of the GP The template could be as the 24 month report, or anther format, will see ?

a. Progress report of working groups

The WGL must organize the report of the scientific activities inside their WG for the final report that must be sent One month after the end of the GP.

• Number of active participants from COST countries

The number of participants is always around 30 - 45, depending on the thematic of the meeting.

• <u>Number of collaborative applications submitted for funding in EU or national calls, with a</u> <u>special focus on contracts signed with European industry.</u>

The 24 Month report shows that some collaborative projects have been submitted

- Number and quality (impact factors, citations) of collaborative peer-reviewed publications, A large number of Action laboratories have a excellent publication policy.
- Number of Short-Term Scientific Missions (STSM) supported by the Action. The numbers of STSM has increased during the GP2 and GP3 (# 6 / GP)

9. Scientific planning

a. Scientific strategy

We change some of the objectives and reinforce the structure of the Action for the last GP.

1 Putting all the means employed to support partners in their efforts to submit projects at European level H2020

2 Better integrate SMES in the dynamics of collaboration between partners and supporting student employability through better interface academy / industry

3 Increase skills in the analysis of partners' biological data and database

4 Clearly demonstrate to the whole European scientific community the interest of our approach in modulating the immune system by ion channels,

5 Increase collaboration between scientists and clinicians,

To reach these goals, we plan some specific activities as follow:

- 1- Small meeting is planned for seminar around the idea to submit a H2020 project
- 2- Ask the SMEs about what do they expected from partners of the Action
- 3- TS planned in Spain will give to the members the means for reach this goal
- 4- We will send all together the same text to our all respective national representatives to Europe, the same text on the scientific goals of our Action
- 5- We will invited more clinicians into our Action for the last two meetings

b. Action Budget Planning

The GP4 WP and Budget have ne not yet been submitted to the COST. The Chair will do that after the MC with the definitive version discussed by the MC members

COST Action BM1406 Annex A of the Grant Agreement from 2018-05-01 to 2019-03-30

Networking Tools	Quantity	Budget
Meetings	2	EUR 78 970.00
Training Schools	1	EUR 17 360.00
Short Term Scientific Missions (STSM)	6	EUR 15 000.00
ITC Conference Grant	2	EUR 3 000.00
COST Action Dissemination	1	EUR 2 000.00
Other Expenses Related to Scientific Activities (OERSA)	EUR 0.00	
Total Science Expenditure	EUR 116 330.00	
Financial and Scientific Administration and Coordination (FSAC) - MAX. 15%	EUR 17 449.50	
Total Grant Request		EUR 133 779.50

c. Long-term planning (including anticipated locations and dates of future activities)

Planned: 2 last meetings and one training school,

- 1- Seillac, France in October 2018 all WG (slide n°23)
- 2- Vienna, Austria in February 2019 (slide n°24)
- 3- Training school in July 18 in Madrid, Spain (slide N° 21)

d. Dissemination planning

The 24month report evaluation shows that our website must be improved. We plan to put each Action members with a short text explaining what is the main thematic of his laboratory and some help on the website to communicate towards the scientific area. People will send to the webmaster some news about publications or all information about science.

A special issue has been planned for June 18 in Curent Opinion in Immunol.

10. Requests for new members

Prof. Netea, The Netherlands (unanimous acceptation)

11. Non-COST applications to the Actions

None

12. AOB No

13. Location and date of next meeting,

Seillac, France from 2 - 5 Oct 2018 (slide N°23) 14. Summary of MC decisions

- New GP working plan to submit to COST
- Improvement of the Action website
- Preparation of the Seillac' meeting
- Preparation of the scientific program of the training school
- Planning of Vienna' meeting
- Preparation of the final report
- Improvement of the website.

15. Closing





- b. Action budget status
- Budget GP3 130,383,92 euros
 Budget GP4 planned 133, 838. oo euros
- b. Management
- GP4 budget has only be submitted to the MC
- and will be submitted to COST after your validation
- c. STSM status and new applications Applicants, with Barbara, MC and COST approvals "Permanent call" in BM1406 Action

- Works flow Red line:

 Remaining procedure: fill the form and send a project (2 pages) to Barbara M.
 Core committee vote (eMail)

Up to a maximum of 3500 euros for a maximum of 91 days. d that it's a contrib tion for a mission and not a glo

4. Update from the Action Chair

d. GP3 report Short Term Scientific Missions

Bank Wink Wing P Joseph y Libors, Usaka Joseph y Lib	Mr Juan José Martínez		a Arrixaca	Hamburg (DE),	PhD. Student	2 500,00	2017-05-02 to 2017-07-31 (1 flays)
Paper, Coola and Membrane Thypothology 1850.0 1860.0	Ms Inès Vieira da Silva		University of Lisbon, Lisboa	Pablo Pelegrin, BioMedical Research Institute of Murcia (IMIB-Arrixaca), Murcia (ES),		2 500,00	2017-09-10 to 2017-12-09 (S days)
Anne Mateix Physiciality and Metabolism, 1 General A, Phol. D017/06-1100 2017-06-50 (2 Mideral F Phol B, Nemmer Tr. Regar Chemily Soldert 2 000.00	ESTER Katja	F	Zagreb, Croatia	and Membrane Physiology	ESR	1 850.00	2017-06-19 to 2017-07-09 (2 days)
Rum Marriel Funny Sussex Constants Constants <thconstants< th=""></thconstants<>	Anna-Maria Miederer	F	Prof. B. Niemever	Physiology and Metabolism, 1 Geneva 4, Switzerland		2 500.00	2017-06-11to 2017-06-30 (21 days)
Ruth Murrell L. Univ Inserm U1059 Nutrition. Croissance et	Ruth Murrell- Laonado	F	Univ Sussex, UK	Inserm U1069 Nutrition, Croissance et cencer	PI	1 000.00	2017-06-11to 2017-06-15 (5 days)
	Stéphanie Chadet	F	Ruth Murrell L. Univ	Inserm U1059 Nutrition, Croissance et	post doc	680.00	2017-08-05 to 2017-08-2017

5. Promotion of gender balance and of Early Stage Researchers (ESR)

- MC committee
- Gender ratio
 MC + substitutes = 13 w/ 23
- Sex ratio = 50%
- Meeting in Dublin 27 w/ 48
- STSM = majority of women 5/6







item	Evaluation by rapporteur	
L Review of Progress	The Action is progressing appropriately with achievement of half of the MoU objectives and delivery of half of the MoU deliverables	Good
II. Review of the Networking	The subject of the action and the groups involved suggest that the action might have a great impact "the short to long term scientific, technological, and jor scoleconomic changes produced by a COST Action, directly or indirectly, intended or unintended" but more information would be necessary to clearly evaluate this topic.	Very good
III. Review of Impacts	Multiple highly significant impacts are reasonably foreseen for the future OR one highly or moderately significant impact is already observed [Very Good]	Very good
IV. Review of Dissemination and exploitation of Action results	The activities undertaken focusing on dissemination and exploitation were ineffective [Poor]	0
V. Review of Action Success(s)	The ACTION states as a point of success the occurrence of 5 meetings. This is interesting but there is no information on the participation of the members on these meetings, notifier the minutes for the meetings. A very important achievement was the publication of a co-edited book "NLR Proteins, Methods in Molecular Biology"	Good/?
VI. Review of the management of the Action budgets	Budget was spent bringing to the meeting invited speakers that represented added valued for the Action. Budget was spent bringing to the meeting invited speakers that represented added valued for the Artinn	Very good

7. Update from the COST Association

• Final report ? No template available but based on the 24 Months template • Dates ?

8. Follow-up of MoU objectives

a. Success will evaluated thank to:

- Number of active participants from COST countries
- Number of collaborative applications submitted for funding in EU or national calls, with a special focus on contracts signed with European industry.
- Number and quality (impact factors, citations) of collaborative peer-reviewed publications,
- Number of Short-Term Scientific Missions (STSM) supported by the Action.



8. Follow-up of MoU objectives

a. Progress report of working groups

All WG, collaborations, student exchanges, papers, pre-review, submitted projects?

WG3 collaborations,

8. Follow-up of MoU objectives

b. 24 month evaluation report:

 Information from WGI I.B. Progress with MoU objectives and deliverables and additional outputs

FP7/H2020 Proposals and projects This table contains FP7/H2020 proposals/ projects spinning off from Action activities and including in the proposing consortium at least three Action participants from at least three different countries participating in the Action.

9. Scientific planning a. Scientific strategy (as defined on MoU) OBJ1. Available data managing and validation strategies consensus for identified targets, OBJ 2. Identification of target diseases, OBJ 3. Translating OBJ1 and 2 into preclinical animal models. OBJ 4. Therap Specific goals for the GP4 Actions / BM1406 / Period 4 / Goals COST Action BM1408, Sumetione And Notestar Breaker fan Channels and Immune Response Taxand a gibbel s Verlipter status: AGA HOP Cred. Period stat-basis: 2019-05-01 Period oncidate: 2019-05-00 Grant Parled Goals Actor Organ

9. Scientific planning

a. Goals of the GP4

- 1 Putting all the means employed to support pa 2 Better integrate SMES in the dynamics of collaboration between partners and s through better interface academy / industry 3 Increase skills in the analysis of partners' biological data and database 4 Clearly demonstrate to the whole European scientific co immune system by ion channels,
- 5 Increase collaboration bet
- How to reach these goals?
- For 1: must be defined
- For 2: SMES ' roles have been under

- For 3: training school planned in Spain
- For 4: we will all send a request to our national Euro
- For 5: I would like to have more clinicians in the last two meetings

9. Scientific planning

b. Action Budget Planning GP4 total amount:133, 833.00 euros COST Action BM1406 Annex A of the Grant Agreement from 2018-05-01 to 2019-03-30
 Networking Tools
 Quarity
 Budget

 Meetings
 2
 EUR 78 50'00'

 Training Schools
 1
 EUR 71 200'00'

 Short Tem Scientific Masions (\$TSM)
 6
 EUR 150'00'

ITC Conference Grant	2	EUR 3 000.00
COST Action Dissemination	1	EUR 2 000.00
Other Expenses Related to Scientific Activities (OERSA)	0	EUR 0.00
Total Science Expenditure		EUR 116 330.00
Financial and Scientific Administration and Coordination (FSAC) - MAX. 15%	15 %	EUR 17 449.50
Total Grant Request		EUR 133 779.50



9. Scientific planning

- d. ITC conferences Grants
- The following eligibility criteria Conference Grants are exclusively reserved for PhD students and ECI's with a primary affiliation in an institution located in an ITC.
- The applicant must make an oral/poster presentation at the conference in question and must be listed in the official event/conference programme. The main subject of the oral presentation | poster presentation | experiment of the approved conference must be on the topic of the Action and must acknowledge COST (see Section 4).
- The participation of each applicant must be pre-approved by the Action MC. Attendance at European conferences is preferred. However, conferences held elsewhere can also be considered.

Bosnia-Herzegovina, Bulgaria, Cyprus, Czech Republic, Estonia, Croatia, Hungary, Lithuania, Latvia, Luxembourg, Malta, Montenegro, Poland, Portugal, Romania, Slovenia, Slovakia, the former Yugoslav Republic of Macedonia, Republic of Serbia and Turkey.

9. Scientific planning

- d. Dissemination planning (Publications and outreach activities)
- Official Website
 - INTRANET (people and lab's) when you click you've get all details of the chosen
 - peopleTo be improved with newsletters, Scientific reports, MC reports
- Facebook
 Everybody has access on the page
- Publications
- Preparation of a special issue for a targeted immunology journal
 Newsletters
- Dissemination meeting ?



10. Requests for new members	
New members / new countries	
The Netherlands ? National representative must be contacted	
11. Non-COST applications to the Actions	
• NO	
12. AOB ?	





5